Takeda’s Dengue Vaccine Proves 4.5-Year Protection

June 10, 2022
Takeda Pharmaceutical’s tetravalent dengue vaccine TAK-003 has demonstrated efficacy in children and adolescents through four and a half years after vaccination, according to the latest global PIII data presented on June 9. In a long-term exploratory analysis of the TIDES...read more